Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PDXK | O00764 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29880065 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPK1SMN1; SMN2POLBPDXK | |
| SCHEMBL22690074 | 0.83 | SMN1; SMN2 (0.50) | ALDH1A1MAPK1SMN1; SMN2POLBPDXK | |
| SCHEMBL29374065 | 0.83 | SMN1; SMN2 (0.50) | ALDH1A1MAPK1SMN1; SMN2POLBPDXK | |
| SCHEMBL15211379 | 0.83 | LMNA (0.36) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL13237026 | 0.81 | ALDH1A1 (0.38) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL1710186 | 0.81 | SMN1; SMN2 (0.42) | ALDH1A1MAPK1SMN1; SMN2POLBKDM4E | |
| SCHEMBL7343198 | 0.80 | MAPK1 (0.39) | ALDH1A1MAPK1SMN1; SMN2POLBPDXK | |
| SCHEMBL31353296 | 0.80 | POLB (0.42) | ALDH1A1MAPK1SMN1; SMN2POLBPDXK | |
| SCHEMBL15819989 | 0.79 | POLB (0.44) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL1710157 | 0.78 | PDXK (0.39) | MAPK1SMN1; SMN2POLBPDXKLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117355521-A | Heteroaryl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| CN-110392681-B | Tosylacetate-based compounds and derivatives thereof as PHGDH inhibitors | 勃林格殷格翰国际有限公司 | 2022-11-25 | — | — | CN | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-19 | — | — | US | disclosed |
| US-20130267513-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2013-10-10 | — | — | US | disclosed |
| EP-2569293-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | Medical Research Council Technology (GB) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141756-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141756-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2011-11-17 | — | — | WO | disclosed |
| EP-2344477-A1 | SMALL MOLECULE BRADYKININ B2 RECEPTOR MODULATORS | Jerini AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010031589-A1 | SMALL MOLECULE BRADYKININ B2 RECEPTOR MODULATORS | JERINI AG (DE) | 2010-03-25 | — | — | WO | disclosed |
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-05-06 | — | — | US | disclosed |
| US-6531475-B1 | CRF receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2001087885-A1 | CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | PHGDH, G6PD, PHPT1 | ALDH1A1 168/4885MAPK1 316/4885SMN1; SMN2 4482/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | ALDH1A1 3026/4885MAPK1 3772/4885SMN1; SMN2 4823/4885 |
| US-20040157851-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | ALDH1A1 1499/4885MAPK1 4062/4885SMN1; SMN2 786/4885 |
| US-20130267513-A1 | PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2 | LRRK2, PARK7, GRK3 | ALDH1A1 4327/4885MAPK1 226/4885SMN1; SMN2 1043/4885 |
| US-20040087589-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRHR2, MC2R | ALDH1A1 1499/4885MAPK1 4062/4885SMN1; SMN2 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.